Evidence map›Paper›PMID 41782384›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy.

Minghai Ma, Xing Li, Minxuan Jing, Zezhong Yang, Jiale He, Jianpeng Li, Xiao Liang, Yunzhong Jiang, Rou Huang, Yuanquan Zhang and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Minghai MaDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Xing LiDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Minxuan JingDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Zezhong YangDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Jiale HeDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Jianpeng LiDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Xiao LiangDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Yunzhong JiangDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Rou HuangDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Yuanquan ZhangDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Yuanchun PuDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Jiawei XiuDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Yutong ChenDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Kaibo MiDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Pu ZhangDepartment of Urology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Lei WangDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Jinhai FanDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.ORCID https://orcid.org/0000-0002-0153-1159

Funding

Key Research and Development Program of Shaanxi Province 2024SF2-GJHX-34Key Research and Development Program of Shaanxi Provincial Health Commission 2025YF-29National Natural Science Foundation of China 82472145National Natural Science Foundation of China 82570903
6 · The paper itself

Abstract

Intravesical chemotherapy for bladder cancer remains limited by poor efficacy and significant toxicity, imposing profound physical and psychological burdens on patients. While several physical-assisted approaches comprising hyperthermic intravesical chemotherapy and electromotive drug administration have been investigated to enhance the chemotherapy, but limited in clinical application due to their technical complexity and high costs. Herein, we introduce a simple yet powerful approach: utilizing programmable mechanical pressure as a therapeutic enhancer to establish a mechano-chemotherapy strategy. We demonstrate that controlled pressure activates the mechanosensitive ion channel Piezo1 in bladder cancer, triggering a calcium ion cascade that transiently and reversibly amplifies mechanosensitivity and membrane permeability. This force-controlled process obviously enhances intracellular accumulation of standard chemotherapeutics, including Doxorubicin (DOX) and Mitomycin-C (MMC), leading to significantly increased tumor cell apoptosis. Crucially, mechano-chemotherapy potently enhances antitumor efficacy while mitigating dose-limiting mucosal toxicity in orthotopic models. In a word, this work establishes Piezo1-mediated mechano-chemotherapy as a readily translatable strategy, transforming mechanical force into a safe and effective tool for optimizing cancer treatment.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsIon ChannelsMitomycinUrinary Bladder NeoplasmsAdministration, IntravesicalAnimalsApoptosisCell Line, TumorDoxorubicinFemaleHumansMiceAntineoplastic AgentsDoxorubicinIon ChannelsMitomycinPIEZO1 protein, humanbladder cancerchemotherapyintravesical instillationmechanical forcepiezo1 channel

Identifiers

PMID41782384
PMCPMC13170195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.